# US 11,078,258 B2 · Methods of treating and preventing Staphylococcus aureus infections and associated conditions > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,078,258 B2 - Document ID: US11078258B2 - Status: Granted - Kind: B2 - Application number: 16/860,716 - Filed: 2020-04-28 - Published: 2020-12-17 - Granted: 2021-08-03 - Earliest claimed: 2011-06-19 - Assignees: New York University - Applicants: New York University - Inventors: Victor J. Torres; Francis Alonzo, III - Web page: https://patentgrep.com/patent/US11078258B2 ## CPC - C07K 16/1271: Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G) - A61K 31/7088: Compounds having three or more nucleosides or nucleotides - A61K 31/724: Cyclodextrins - A61K 38/164: {from bacteria} - A61K 39/085: Staphylococcus - A61K 39/40: bacterial - A61P 9/00: Drugs for disorders of the cardiovascular system - A61P 11/00: Drugs for disorders of the respiratory system - A61P 17/00: Drugs for dermatological disorders - A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like - A61P 19/02: for joint disorders, e.g. arthritis, arthrosis - A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics - A61P 31/04: Antibacterial agents - A61P 37/04: Immunostimulants - A61P 39/02: Antidotes - C07K 16/12: against material from bacteria - G01N 33/5014: {for testing toxicity} - G01N 33/5047: {Cells of the immune system} - G01N 33/56938: {Staphylococcus} - A61K 2039/505: {comprising antibodies} - C07K 2317/31: multispecific - C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding - G01N 2333/31: from Staphylococcus (G) - G01N 2469/10: Detection of antigens from microorganism in sample from host - G01N 2500/10: involving cells - G01N 2800/56: Staging of a disease; Further complications associated with the disease - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract The present invention relates to methods and compositions for preventing and treating Staphylococcus aureus in a subject. Therapeutic compositions of the present invention comprise leukocidin E and/or D proteins or polypeptides and anti-leukocidin E and/or D antibodies. The invention further relates to methods of identifying inhibitors of LukE/D cytotoxicity and inhibitors of LukE/D-leukocyte binding. ## Claims ### Claim 1 A composition for immunizing a subject against S. aureus infection, said composition comprising: an isolated Leukocidin E (LukE) polypeptide, said polypeptide comprising an amino acid sequence of 50-200 amino acid residues of SEQ ID NO: 11; and a pharmaceutically acceptable carrier. ### Claim 2 (depends on 1) The composition of claim 1 further comprising: an isolated Leukocidin D (LukD) polypeptide, said polypeptide comprising an amino acid sequence of 50-200 amino acid residues of SEQ ID NO: 22. ### Claim 3 (depends on 1) The composition of claim 1 further comprising: an adjuvant. ### Claim 4 (depends on 3) The composition of claim 3, wherein the adjuvant is selected from the group consisting of flagellin, Freund's complete adjuvant, Freund's incomplete adjuvant, aluminum hydroxide, lysolecithin, pluronic polyols, polyanions, peptides, oil emulsion, dinitrophenol, iscomatrix, and liposome polycation DNA particles. ### Claim 5 A composition for immunizing a subject against S. aureus infection, said composition comprising: an isolated Leukocidin D (LukD) polypeptide, said polypeptide comprising an amino acid sequence of 50-200 amino acid residues of SEQ ID NO: 22; and a pharmaceutically acceptable carrier. ### Claim 6 (depends on 5) The composition of claim 5 further comprising an isolated Leukocidin E (LukE) polypeptide, said polypeptide comprising an amino acid sequence of 50-200 amino acid residues of SEQ ID NO: 11. ### Claim 7 (depends on 5) The composition of claim 5 further comprising: an adjuvant. ### Claim 8 (depends on 5) The composition of claim 5, wherein the adjuvant is selected from the group consisting of flagellin, Freund's complete adjuvant, Freund's incomplete adjuvant, aluminum hydroxide, lysolecithin, pluronic polyols, polyanions, peptides, oil emulsion, dinitrophenol, iscomatrix, and liposome polycation DNA particles.